Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Thalassemia, Hypertension, Pulmonary
Interventions
Sildenafil
Drug
Lead sponsor
Carelon Research
Other
Eligibility
7 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oakland, California
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Enrolling by invitation No phase listed Observational

MRI and Computational Simulation Cardiology Study

NCT03149341
Conditions
Congenital Heart Disease, Pulmonary Hypertension
Interventions
Magnetic Resonance Imaging
Other
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions
inhaled nitric oxide, Placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
23 Weeks to 29 Weeks
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Data Collection
Other
Lead sponsor
Namita Sood
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Pulmonary Hypertension
Interventions
Warfarin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Persistent Fetal Circulation Syndrome, Persistent Pulmonary Hypertension of Newborn
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 8 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Oakland, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Conditions
Congenital Diaphragmatic Hernia
Interventions
Goldbal Detachable Balloon and delivery microcatheter
Device
Lead sponsor
Michael A Belfort
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Conditions
Pulmonary Hypertension
Interventions
iNO, Non-invasive nitric oxide
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Bronchopulmonary Dysplasia, Bronchopulmonary Dysplasia Associated Pulmonary Hypertension, Pulmonary Hypertension, Premature Birth, Chronic Lung Disease of Prematurity
Interventions
Enteral L-citrulline
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 30 Weeks
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Conditions
Bronchopulmonary Dysplasia (BPD), Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Up to 30 Weeks
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
2
States / cities
Mountain View, California • Palo Alto, California
Conditions
Preeclampsia
Interventions
Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
Other
Lead sponsor
Indiana University
Other
Eligibility
26 Weeks and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Sickle Cell Disease
Interventions
Albuterol
Drug
Lead sponsor
Duke University
Other
Eligibility
5 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Infant,Premature, Bronchopulmonary Dysplasia, Pulmonary Hypertension
Interventions
L-Citrulline
Drug
Lead sponsor
University of Utah
Other
Eligibility
14 Days to 3 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational Accepts healthy volunteers Results available

Cardiovascular Complications of Sickle Cell Disease

NCT01044901
Conditions
Sickle Cell Disease
Interventions
MRI, Transthoracic Echocardiography, tonometry, EKG
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypertension
Interventions
Sildenafil Oral Suspension, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions
LungGuard, BAROGuard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
Conditions
Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
Interventions
Inhaled Prostaglandin E1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more